Skip to main content
. 2020 May 5;37(2):168–173. doi: 10.5114/ada.2020.94835

Table 1.

Summary: the influence of biological treatment on body mass in chronic plaque psoriasis

Biological therapy Body mass influence Commetary Literature
TNF-α inhibitors:
 Infliximab Weight gain Weight-dependent dosing allows heavier individuals to achieve efficient therapy response

  1. Puig L. (2011) Journal of the European Academy of Dermatology and Venereology; literature review article

  2. Tan E, Baker C, Foley P. (2013) Australasian Journal of Dermatology; retrospective observational study, N = 143, observational period: 48 weeks
 Adalimumab Weight gain 9-years retrospective study reported beneficial response irrespective of body weight. Adalimumab influence in obese needs further research

  1. Puig L. (2011) Journal of the European Academy of Dermatology and Venereology; literature review article

  2. Di Lernia V, Tasin L, Pellicano R, et al. (2012) Journal of Dermatological Treatment; retrospective observational study, N = 194, follow-up: 2 years

  3. Chiricozzi A, Zangrilli A, Bavetta M, et al. (2017) Journal of the European Academy of Dermatology and Venereology; retrospective observational study, N = 316, observational period: 9 years
 Etanercept Weight gain The most prominent weight gain. Might be beneficial to narrow treatment target to individuals with normal BMI

  1. Puig L. (2011) Journal of the European Academy of Dermatology and Venereology; literature review article

  2. Saraceno R, Schipani C, Mazzotta A, et al. (2008) Pharmacological Research; retrospective observational study, N = 230, observational period: 48 weeks
IL-12/23 inhibitor:
 Ustekinumab No Diminishing clinical response in patients above 100kg. Individual weight adjustment might improve compliance

  1. Puig L. (2011) Journal of the European Academy of Dermatology and Venereology; literature review article

  2. Yanaba K, Umezawa Y, Ito T, et al. (2014) Archives of Dermatological Research; retrospective cohort study, N = 111, observational period: 3 years

  3. Gisondi P, Conti A, Galdo G. (2013) British Journal of Dermatology; prospective cohort study, N = 162
IL-17A inhibitors:
 Secukinumab No Good alternative for overweight and obese patients’ population

  1. Tamakura S, Takahashi A, Inoue Y, et al. (2018) Journal of Dermatology; retrospective observational study, N = 68, observational period: 7 months
 Ixekizumab No Good alternative for overweight and obese patients’ population

  1. Egebeg A, Wu J, Korman N, et al. (2018) Journal of the American Academy of Dermatology; randomized controlled 3-trial study, N1 = 1296, N2 = 1224, N3 = 1346